Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03215277 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT03215277 is a Phase 2 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 76 participants.
The verdict
NCT03215277, a Phase 2 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).
Interventions
- OTHER Placebo
- DRUG Bimekizumab
- DRUG Certolizumab pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2020-05-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03215277
The ClinicalTrials.gov registry entry for NCT03215277 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03215277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03215277 about?
NCT03215277 is a clinical study titled "A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis". The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).
What is the current status of trial NCT03215277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2017-10-04. Estimated completion is 2020-05-25.
What interventions are being tested in trial NCT03215277?
The interventions under investigation include: Placebo (OTHER), Bimekizumab (DRUG), Certolizumab pegol (DRUG).
Who is sponsoring clinical trial NCT03215277?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.